Eyepoint Pharmaceuticals Ownership
| EYPT Stock | USD 9.72 0.06 0.62% |
Shares in Circulation | First Issued 2002-09-30 | Previous Quarter 64.6 M | Current Value 69.8 M | Avarage Shares Outstanding 11 M | Quarterly Volatility 16.3 M |
Eyepoint Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The book value of Eyepoint Pharmaceuticals was currently reported as 4.34. The company recorded a loss per share of 2.42. Eyepoint Pharmaceuticals last dividend was issued on the 9th of December 2020. The entity had 1:10 split on the 9th of December 2020. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Eyepoint Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people. To learn more about Eyepoint Pharmaceuticals call Nancy Lurker at 617 926 5000 or check out https://eyepointpharma.com.Besides selling stocks to institutional investors, Eyepoint Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Eyepoint Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Eyepoint Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Eyepoint Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Eyepoint Pharmaceuticals are currently held by insiders. Unlike Eyepoint Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Eyepoint Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Eyepoint Pharmaceuticals' insider trades
Eyepoint Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eyepoint Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyepoint Pharmaceuticals backward and forwards among themselves. Eyepoint Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eyepoint Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 1.6 M | Perceptive Advisors Llc | 2025-03-31 | 1.5 M | Goldman Sachs Group Inc | 2025-03-31 | 1.5 M | Patient Square Capital | 2025-03-31 | 1.5 M | T. Rowe Price Associates, Inc. | 2025-03-31 | 1.4 M | Essex Woodlands Health Ventures | 2025-03-31 | 1.2 M | Finepoint Capital Lp | 2025-03-31 | 1.1 M | 5am Venture Management, Llc | 2025-03-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 864.1 K | Cormorant Asset Management, Llc | 2025-03-31 | 8.3 M | Suvretta Capital Management, Llc | 2025-03-31 | 6.8 M |
Eyepoint Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyepoint Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyepoint Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eyepoint Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eyepoint Pharmaceuticals Outstanding Bonds
Eyepoint Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eyepoint Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eyepoint bonds can be classified according to their maturity, which is the date when Eyepoint Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| EXXON MOBIL P Corp BondUS30231GAN25 | View | |
| EXXON MOBIL P Corp BondUS30231GBK76 | View | |
| EXXON MOBIL P Corp BondUS30231GBN16 | View | |
| EXXON MOBIL P Corp BondUS30231GBM33 | View | |
| EXXON MOBIL P Corp BondUS30231GBG64 | View | |
| EXXON MOBIL P Corp BondUS30231GBF81 | View | |
| EXXON MOBIL P Corp BondUS30231GBJ04 | View | |
| Exxon Mobil 244 Corp BondUS30231GBE17 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.